Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH (NCT07335601)
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies
🩺 Plain-English Summary (8th-Grade Level)
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of California San Diego — La Jolla, California
- University of California Los Angeles Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- University of Colorado — Aurora, Colorado
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Northwestern University — Chicago, Illinois
- The University of Chicago Medicine — Chicago, Illinois
- Mayo Clinic — Rochester, Minnesota
- University of Nebraska — Omaha, Nebraska
- Northwell Health Inc, Center for Liver Disease and Transplantation — Manhasset, New York
- NY Presbyterian- Weill Cornell Medicine — New York, New York
- Vanderbilt University Medical Center (VUMC) — Nashville, Tennessee
- Dallas Methodist — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- Intermountain Medical Center — Murray, Utah
- University of Virginia Health System — Charlottesville, Virginia
- University Health Network - Toronto General Hospital (TGH) — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (302) 640-2217
Email: dhernandez@madrigalpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in MASH - Metabolic Dysfunction-Associated Steatohepatitis
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Chandler, Arizona
- Rezdiffra Pregnancy and Lactation Registry — West Conshohocken, Pennsylvania
Explore by condition: All MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.